TABLE 3.
Multivariable analysis to determine the factors associated with not completing latent tuberculosis infection treatment among participants who initiated it.
| Variables | Total | Not completing treatment | Univariable analysis | Multivariable analysis | ||
|
|
|
|
|
|||
| n (column%) | n (row%) | RR (95% CI) | P-value | aRR (95% CI) | P-value | |
| Participants | 32,834 (100.0) | 4,959 (15.1) | ||||
| Sex | ||||||
| Female | 29,158 (88.8) | 4,377 (15.0) | 1 | 1 | ||
| Male | 3,676 (11.2) | 582 (15.8) | 1.06 (0.98–1.15) | 0.159 | 1.10 (1.01–1.20) | 0.027 |
| Age (years) | ||||||
| <20 | 1,816 (5.5) | 199 (11.0) | 0.58 (0.50–0.67) | <0.001 | 0.52 (0.44–0.61) | <0.001 |
| 20–34 | 2,938 (8.9) | 560 (19.1) | 1 | 1 | ||
| 35–49 | 14,092 (42.9) | 2,109 (15.0) | 0.79 (0.73–0.86) | <0.001 | 0.79 (0.72–0.86) | <0.001 |
| 50–64 | 13,021 (39.7) | 1,955 (15.0) | 0.80 (0.73–0.87) | <0.001 | 0.77 (0.70–0.84) | <0.001 |
| ≥65 | 967 (2.9) | 136 (14.1) | 0.74 (0.62–0.88) | 0.001 | 0.69 (0.57–0.82) | <0.001 |
| Place of residencea | ||||||
| Rural area | 3,444 (10.5) | 527 (15.3) | 1 | 1 | ||
| Small to medium-sized city | 11,098 (33.8) | 1,893 (17.1) | 1.11 (1.02–1.21) | 0.021 | 1.18 (1.08–1.29) | <0.001 |
| Metropolitan city | 18,287 (55.7) | 2,539 (13.9) | 0.91 (0.83–0.99) | 0.024 | 1.05 (0.96–1.15) | 0.317 |
| Income levelb | ||||||
| Low | 15,371 (46.8) | 2,287 (14.9) | 1 | 1 | ||
| Moderate low | 9,433 (28.7) | 1,389 (14.7) | 0.99 (0.93–1.05) | 0.744 | 0.98 (0.92–1.04) | 0.528 |
| Moderate high | 4,565 (13.9) | 758 (16.6) | 1.12 (1.04–1.20) | 0.004 | 1.11 (1.03–1.20) | 0.007 |
| High | 3,202 (9.8) | 489 (15.3) | 1.03 (0.94–1.12) | 0.571 | 1.08 (0.98–1.18) | 0.127 |
| Charlson comorbidity index | ||||||
| Score 0 | 14,182 (43.2) | 2,078 (14.7) | 1 | 1 | ||
| Score 1 | 11,178 (34.0) | 1,696 (15.2) | 1.04 (0.98–1.11) | 0.180 | 1.04 (0.98–1.11) | 0.166 |
| Score 2 | 4,838 (14.7) | 731 (15.1) | 1.04 (0.96–1.12) | 0.342 | 1.05 (0.97–1.14) | 0.238 |
| Score 3 or more | 2,636 (8.0) | 454 (17.2) | 1.18 (1.08–1.30) | 0.001 | 1.20 (1.09–1.32) | <0.001 |
| Type of treatment centre | ||||||
| Private hospitals | 18,992 (57.8) | 2,398 (12.6) | 1 | 1 | ||
| Public health centres | 13,842 (42.2) | 2,561 (18.5) | 1.47 (1.40–1.55) | <0.001 | 1.48 (1.40–1.56) | <0.001 |
| Type of initial regimen | ||||||
| 3HR | 27,118 (82.6) | 4,166 (15.4) | 1 | 1 | ||
| 4RIF | 3,555 (10.8) | 427 (12.0) | 0.78 (0.71–0.85) | <0.001 | 0.82 (0.75–0.90) | <0.001 |
| 9INH | 2,161 (6.6) | 366 (16.9) | 1.10 (1.00–1.22) | 0.050 | 1.28 (1.16–1.41) | <0.001 |
Multivariable models adjusted for everything in the table. 3HR, 3-months of rifampin and isoniazid combination therapy; 9INH, 9-months of isoniazid monotherapy; 4RIF, 4-months of rifampin monotherapy; aRR, adjusted relative risk; CI, confidence interval; RR, relative risk. aFive people had missing data. b263 people had missing data.